Silicone Tubing for Pharmaceutical Manufacturing: Extractables, Leachables, and Regulatory Compliance

Silicone tubing is the fluid transfer material of choice in pharmaceutical manufacturing — present in virtually every bioprocessing facility, sterile fill-finish line, and drug formulation suite in the world. Its combination of chemical inertness, thermal stability, steam sterilizability, and low extractables profile makes it uniquely suited to the demands of drug manufacturing, where every material in contact with a drug product must be rigorously characterized and its safety demonstrated.

Yet pharmaceutical silicone tubing is one of the most technically complex procurement decisions in the industry. The regulatory framework governing drug-contact materials — spanning USP <665>, ICH Q3C/Q3D, EU GMP Annex 1, and FDA 21 CFR Part 211 — is detailed, evolving, and frequently misunderstood. The extractables and leachables (E&L) testing required to qualify silicone tubing for pharmaceutical applications is more demanding than the biocompatibility testing required for medical devices. And the consequences of inadequate qualification — drug contamination, batch rejection, regulatory action, or patient harm — are severe.

This guide gives pharmaceutical engineers, quality assurance professionals, and procurement managers the complete technical and regulatory framework for specifying, qualifying, and sourcing silicone tubing for pharmaceutical manufacturing applications.

Part 1: Why Pharmaceutical Applications Demand More Than Medical Device Standards

The first thing pharmaceutical engineers must understand is that medical device certifications — USP Class VI, ISO 10993-5, FDA 21 CFR 177.2600 — are necessary but not sufficient for pharmaceutical manufacturing applications.

The Fundamental Difference

Why USP Class VI Is Not Enough for Pharmaceutical Use

USP Class VI is a biological safety test — it evaluates whether a material causes acute biological reactions in animals at defined extraction conditions. It does not:

• Identify or quantify specific chemical extractables

• Evaluate extractables at pharmaceutical process conditions (high temperature, aggressive solvents, long contact times)

• Assess the impact of extractables on drug product stability or efficacy

• Meet the requirements of ICH Q3C/Q3D for elemental impurities and residual solvents

A silicone tubing that passes USP Class VI testing may still release extractables that degrade a sensitive biologic, catalyze drug oxidation, or introduce elemental impurities (platinum, tin) above ICH Q3D permitted daily exposure (PDE) limits.

The correct standard for pharmaceutical drug-contact materials is USP <665> — Plastic Components and Systems Used in Pharmaceutical Manufacturing — which provides a risk-based framework specifically designed for pharmaceutical manufacturing applications.

Part 2: The Extractables and Leachables Framework — Core Concepts

Definitions

Extractables: Chemical compounds that can be released from a material under exaggerated extraction conditions (aggressive solvent, elevated temperature, extended time). Extractables studies characterize the worst-case chemical profile of a material — they represent the universe of compounds that could potentially leach under any process condition.

Leachables: Chemical compounds that actually migrate from a material into the drug product under normal process conditions (actual solvent, actual temperature, actual contact time). Leachables are a subset of extractables — only compounds present in the extractables profile can become leachables.

The E&L relationship:

Leachables⊆ExtractablesLeachables⊆Extractables

Extractables studies are conducted first to characterize the material. Leachables studies then confirm which extractables actually migrate under process conditions and at what concentrations.

The Risk-Based E&L Framework

The industry-standard framework for E&L qualification of pharmaceutical manufacturing materials is defined by:

• BPOG (BioPhorum Operations Group) Extractables Protocol — the most widely used industry standard for single-use bioprocessing systems

• USP <665> — Plastic Components and Systems Used in Pharmaceutical Manufacturing (effective December 2025)

• USP <1665> — Informational chapter on plastic components — guidance on risk assessment and testing

• ICH Q3C — Residual solvents — limits for organic extractables

• ICH Q3D — Elemental impurities — limits for metal extractables (including platinum from platinum-cured silicone)

• ISO 10993-18 — Chemical characterization of medical device materials

The Four-Stage E&L Qualification Process

Stage 1: Material Risk Assessment

Before conducting any testing, assess the risk level of the silicone tubing application:

Higher risk applications require more extensive E&L characterization and lower acceptance thresholds.

Stage 2: Extractables Study

Conduct extraction of silicone tubing samples under exaggerated conditions designed to maximize extractable yield:

• Solvents: Water, 50% ethanol/water, isopropanol, hexane (covers polar and non-polar extractables)

• Temperature: Elevated (typically 40°C or 70°C — above normal process temperature)

• Duration: Extended (typically 24–72 hours — longer than normal process contact)

• Surface area to volume ratio: Exaggerated (higher than process conditions)

Analytical methods:

• GC-MS (gas chromatography-mass spectrometry) — volatile and semi-volatile organics

• LC-MS/MS (liquid chromatography-tandem mass spectrometry) — non-volatile organics

• ICP-MS (inductively coupled plasma-mass spectrometry) — elemental impurities (platinum, tin, silicon)

• TOC (total organic carbon) — total organic extractables screening

• UV/Vis spectroscopy — aromatic compounds screening

Stage 3: Toxicological Risk Assessment (TRA)

For each extractable identified above the Analytical Evaluation Threshold (AET), conduct a toxicological risk assessment:

AET=TTC×Body WeightDaily Dose×Safety FactorAET=Daily Dose×Safety FactorTTC×Body Weight

Where TTC (Threshold of Toxicological Concern) is typically 1.5 μg/day for non-genotoxic compounds (Cramer Class I) per ICH M7 guidance.

The TRA evaluates:

• Whether each identified compound has known toxicity data

• Whether the expected leachable concentration in the drug product exceeds the TTC or compound-specific PDE

• Whether any identified compound is a known genotoxin (requires special treatment per ICH M7)

Stage 4: Leachables Confirmation Study

Conduct extraction under actual process conditions (actual solvent, actual temperature, actual contact time, actual surface area to volume ratio) to confirm that leachable levels in the drug product are below the limits established in the TRA.

Part 3: Platinum — The Critical Elemental Impurity in Platinum-Cured Silicone

Platinum-cured silicone is the only acceptable compound for pharmaceutical manufacturing applications — peroxide-cured silicone releases organic by-products (acetophenone, benzoic acid) that are incompatible with pharmaceutical fluid paths. However, platinum-cured silicone introduces its own elemental impurity consideration: residual platinum catalyst.

ICH Q3D Platinum Limits

ICH Q3D (Guideline for Elemental Impurities) establishes Permitted Daily Exposure (PDE) limits for elemental impurities in drug products. Platinum is classified as a Class 2B element (conditional risk):

Platinum Extractables from Silicone Tubing

The platinum catalyst in platinum-cured silicone is present at very low levels in the finished compound (typically 5–20 ppm total platinum). The fraction that is extractable — and therefore potentially leachable into drug products — is even lower, typically in the range of 0.01–0.1 ppb in aqueous extraction media under normal process conditions.

For most pharmaceutical applications, platinum leachables from well-manufactured platinum-cured silicone tubing are well below ICH Q3D PDE limits. However, this must be confirmed by ICP-MS analysis for each specific tubing grade and process condition — particularly for:

• Parenteral drug products (lower PDE: 10 μg/day)

• Inhalation drug products (very low PDE: 1 μg/day)

• High-temperature applications (CIP at 121°C increases platinum extractability)

• Long contact time applications (>24 hours continuous contact)

What to Request from Your Silicone Tubing Supplier

For pharmaceutical applications, request the following platinum-specific documentation:

• ICP-MS platinum extractables data in water and 50% ethanol at 40°C, 24 hours

• ICP-MS platinum extractables data at process temperature (if >40°C)

• Total platinum content in the compound (ppm) — from compound certificate

• Platinum catalyst type (Karstedt's catalyst or equivalent) — for toxicological reference

• Confirmation that no tin-based catalyst or crosslinker is present (tin is a Class 2A element with lower PDE)

For a complete guide to biocompatibility and chemical compliance certifications for medical silicone, see: USP Class VI, ISO 10993, and FDA 21 CFR 177.2600: Which Certification Do You Actually Need?

Part 4: USP <665> — The New Standard for Pharmaceutical Manufacturing Materials

USP <665> (Plastic Components and Systems Used in Pharmaceutical Manufacturing) became official in December 2025, replacing the previous USP <661> framework for pharmaceutical manufacturing materials. Understanding its requirements is essential for any pharmaceutical manufacturer qualifying silicone tubing after this date.

USP <665> Key Requirements

Scope: USP <665> applies to plastic and elastomeric components (including silicone tubing) used in pharmaceutical manufacturing equipment that contacts drug products, drug substances, or excipients.

Risk-based approach: USP <665> uses a risk-based qualification framework — the extent of testing required depends on the application risk level (contact substance, duration, temperature, route of administration of the drug product).

Extractables testing requirements:

• Aqueous extraction (pH 3, pH 7, pH 10) at 40°C, 24 hours

• Organic extraction (50% ethanol, isopropanol) at 40°C, 24 hours

• Analytical methods: GC-MS, LC-MS/MS, ICP-MS

• Reporting threshold: All compounds identified above the AET must be reported

Toxicological risk assessment: Required for all extractables identified above the AET. The TRA must evaluate each compound against TTC (1.5 μg/day for non-genotoxic) or compound-specific toxicity data.

Change control: Any change to the material composition, manufacturing process, or supplier requires re-qualification under USP <665>.

USP <665> vs. Previous USP <661>

The transition from USP <661> to USP <665> represents a significant increase in the rigor of pharmaceutical material qualification. Silicone tubing suppliers who only have USP <661> compliance data are not meeting the current standard.

Part 5: GMP Requirements for Silicone Tubing in Drug Manufacturing

FDA 21 CFR Part 211 — Current Good Manufacturing Practice

Under FDA cGMP regulations (21 CFR Part 211), equipment used in drug manufacturing must:

21 CFR 211.65 — Equipment construction:"Equipment shall be constructed so that surfaces that contact components, in-process materials, or drug products shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements."

This regulation directly governs silicone tubing selection. The tubing must be demonstrated to be non-reactive (no chemical reaction with the drug), non-additive (no extractables above acceptable limits), and non-absorptive (no drug adsorption that reduces delivered concentration).

21 CFR 211.67 — Equipment cleaning and maintenance:Silicone tubing used in drug manufacturing must be cleanable and sterilizable. For single-use tubing (replaced after each batch), cleaning validation is not required. For multi-use tubing, cleaning validation per FDA guidance must demonstrate that residuals from the previous batch are reduced to acceptable levels.

EU GMP Annex 1 (2022 Revision) — Manufacture of Sterile Medicinal Products

The 2022 revision of EU GMP Annex 1 introduced significant new requirements for materials used in sterile drug manufacturing, directly affecting silicone tubing selection:

Section 4.36 (Single-use systems):"Single-use systems should be qualified for their intended use. The qualification should include... extractables and leachables studies to demonstrate that the materials do not adversely affect the quality of the product."

Section 8.123 (Tubing and connections):Tubing used in sterile manufacturing must be qualified for chemical compatibility, extractables, and integrity. Integrity testing (pressure hold or vacuum decay) is required for critical fluid path connections.

ICH Q10 — Pharmaceutical Quality System

ICH Q10 requires that pharmaceutical manufacturers maintain a documented supplier qualification program for critical materials — including silicone tubing used in drug manufacturing. Key requirements:

• Supplier qualification based on risk assessment

• Documented quality agreement with the supplier

• Change notification requirements for material or process changes

• Periodic re-qualification based on risk

For guidance on building a robust supplier qualification program and conducting remote factory audits of silicone tubing suppliers, see: How to Conduct a Remote Factory Audit of a Chinese Medical Silicone Manufacturer

Part 6: Single-Use Bioprocessing — The Fastest-Growing Pharmaceutical Silicone Application

What Single-Use Bioprocessing Means

Single-use bioprocessing systems (also called disposable bioprocessing systems) use plastic and silicone components that are used once and discarded — replacing the stainless steel vessels, glass columns, and reusable tubing that dominated pharmaceutical manufacturing for decades.

The shift to single-use systems has been driven by:

• Elimination of cleaning validation — single-use components are pre-sterilized and discarded after use, eliminating the need for cleaning validation between batches

• Reduced cross-contamination risk — no carryover between products or batches

• Faster changeover — no cleaning, sterilization, or re-qualification between batches

• Lower capital cost — no investment in CIP/SIP systems for small-scale and clinical manufacturing

• Flexibility — single-use systems can be reconfigured for different products without facility modification

Silicone Tubing in Single-Use Bioprocessing

Silicone tubing is the primary fluid transfer material in single-use bioprocessing systems. Key applications:

Gamma Sterilization for Single-Use Bioprocessing Tubing

Single-use bioprocessing tubing is typically supplied pre-sterilized by gamma irradiation — the preferred sterilization method for single-use systems because:

• No chemical residuals (unlike EtO)

• Compatible with sealed packaging (unlike EtO and autoclave)

• Validated for the complete assembled single-use system (tubing + connectors + bags)

• Consistent, reproducible sterilization dose

Gamma sterilization effects on silicone for bioprocessing:

• Standard dose: 25–50 kGy

• Slight hardening (2–5 Shore A units) — typically acceptable for bioprocessing applications

• Transient increase in extractables immediately post-irradiation — extractables testing should be conducted after a defined post-irradiation hold period (typically 2–4 weeks) to allow free radical recombination

• No significant change in platinum extractables at standard doses

For a complete guide to sterilization method selection and validation for pharmaceutical silicone tubing, see: Sterilization Methods for Medical Silicone Products: Autoclave, EtO, Gamma, and E-Beam Compared

Cell Culture Media Compatibility

For bioreactor and cell culture applications, silicone tubing must be compatible with cell culture media — which contains amino acids, vitamins, growth factors, glucose, and pH buffers. Key considerations:

Cell viability impact: Extractables from silicone tubing can affect cell viability and productivity in bioreactor cultures. Even sub-cytotoxic concentrations of extractables can inhibit cell growth or alter protein expression. Cell culture compatibility testing — growing cells in media that has been in contact with the silicone tubing — is required for bioreactor applications.

Growth factor adsorption: Some growth factors (EGF, FGF, insulin) adsorb onto silicone surfaces, reducing their effective concentration in the media. For media containing expensive growth factors, adsorption testing is recommended.

pH stability: Silicone tubing should not affect media pH. Well-manufactured platinum-cured silicone has minimal impact on pH of neutral aqueous media. Verify pH stability for acidic or basic media formulations.

Part 7: Silicone Tubing for CIP and SIP — Cleaning and Sterilization in Place

For multi-use pharmaceutical manufacturing equipment, silicone tubing must withstand repeated Clean-In-Place (CIP) and Steam-In-Place (SIP) cycles.

CIP Compatibility

CIP systems typically use:

• Caustic wash: 1–2% NaOH at 60–80°C

• Acid wash: 0.5–1% phosphoric acid or nitric acid at 60–80°C

• Sanitization: 70–80% ethanol or 200 ppm peracetic acid

Platinum-cured silicone is compatible with standard CIP chemicals at normal concentrations and temperatures. However, repeated CIP cycling can cause cumulative surface changes — particularly with concentrated caustic solutions at elevated temperatures. Validate CIP compatibility by:

• Conducting accelerated CIP cycling (50–100 cycles) under worst-case conditions

• Measuring extractables before and after CIP cycling — CIP can increase extractables by removing surface oxidation layer

• Verifying dimensional stability after CIP cycling (Shore A hardness, ID/OD measurements)

SIP Compatibility

SIP sterilization uses steam at 121°C or 134°C flowing through the assembled tubing system. Platinum-cured silicone is highly compatible with SIP:

SIP validation requirement: For multi-use tubing in pharmaceutical manufacturing, SIP validation must demonstrate that the sterilization cycle achieves SAL 10−610−6 throughout the tubing system — including the most challenging locations (dead legs, low-flow zones). Biological indicator placement and steam penetration mapping are required.

Part 8: Silicone Tubing Selection Guide for Pharmaceutical Applications

Application-to-Specification Matrix

Silicone Grade Selection: Standard vs. Ultra-Low Extractables

Not all pharmaceutical applications require the same extractables performance. Match the silicone grade to the application risk:

Standard pharmaceutical grade:

• Meets USP <665> extractables requirements at standard test conditions

• Suitable for: buffer transfer, CIP/SIP lines, non-critical fluid paths, bioreactor connections

• Extractables profile: documented by supplier; TOC typically < 5 ppm in aqueous extraction

Ultra-low extractables grade:

• Post-cure treatment to reduce volatile siloxane content

• Additional extraction/washing process to remove surface extractables

• Suitable for: fill-finish fluid paths, high-potency drug contact, sensitive biologics, inhalation drug manufacturing

• Extractables profile: TOC typically < 1 ppm in aqueous extraction; platinum < 0.05 ppb

Post-cured and extracted grade:

• Secondary post-cure at elevated temperature (200°C, 4 hours) to volatilize residual low-molecular-weight siloxanes

• Solvent extraction to remove surface-bound extractables

• Suitable for: most demanding pharmaceutical applications

• Extractables profile: lowest available; verified by GC-MS for cyclic siloxanes (D4, D5, D6)

For guidance on Shore A hardness selection for pharmaceutical pump and transfer applications, see: Silicone Shore A Hardness Explained: How to Select the Right Durometer for Your Medical Application

Part 9: Supplier Qualification for Pharmaceutical Silicone Tubing

Qualifying a silicone tubing supplier for pharmaceutical manufacturing is more rigorous than for medical device applications. The following framework covers the key qualification elements.

Documentation Requirements

A pharmaceutical-grade silicone tubing supplier must provide:

Tier 1: Basic material documentation (all pharmaceutical applications)

• Material composition statement (ingredient list with CAS numbers)

• Confirmation of platinum-cured compound (no peroxide cure, no tin catalyst)

• USP <665> extractables study report (or equivalent BPOG protocol)

• ICP-MS elemental impurities data (platinum, tin, and all ICH Q3D Class 1 and 2 elements)

• Certificate of Analysis (lot-specific, with actual measured values)

• ISO 13485 certificate (current, scope-verified)

• FDA Drug Master File (DMF) reference number (if available — not all suppliers have DMFs)

Tier 2: Enhanced documentation (high-risk applications — biologics, sterile fill-finish)

• Full GC-MS and LC-MS/MS extractables characterization report

• Toxicological Risk Assessment (TRA) for identified extractables

• Cell culture compatibility data (for bioreactor applications)

• Gamma irradiation compatibility data (for single-use systems)

• Post-irradiation extractables data (measured after 2–4 week hold period)

• Particulate cleanliness data (ISO Class 7 cleanroom manufacturing verification)

Tier 3: Process-specific documentation (CIP/SIP, specific drug contact)

• CIP cycle durability data (100 cycles at worst-case conditions)

• SIP cycle durability data (100 cycles at 121°C or 134°C)

• Drug-specific compatibility data (for known high-risk drugs)

• Change control history (any changes to compound, process, or supplier in past 3 years)

The Drug Master File (DMF) — What It Is and Why It Matters

A Drug Master File (DMF) is a confidential submission to FDA that provides detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of drug products. For silicone tubing suppliers, a Type IV DMF covers the tubing material itself.

Why a DMF matters for pharmaceutical procurement:

• Drug product manufacturers can reference the supplier's DMF in their IND/NDA/ANDA submissions — avoiding the need to include confidential supplier information in their own regulatory submissions

• FDA reviewers can access the DMF directly, streamlining the review process

• The existence of an active DMF demonstrates that the supplier has engaged with FDA on their material — a quality indicator

How to verify a DMF: FDA DMF numbers can be verified at: accessdata.fda.gov/scripts/cder/daf/

Not all silicone tubing suppliers have DMFs — particularly smaller manufacturers. The absence of a DMF is not disqualifying, but the supplier must be able to provide equivalent technical information directly to the drug product manufacturer for inclusion in regulatory submissions.

Supplier Audit Focus Areas for Pharmaceutical Applications

In addition to the standard medical device supplier audit elements (ISO 13485 verification, cleanroom inspection, traceability demonstration), pharmaceutical supplier audits should specifically address:

• Compound change control: How does the supplier notify customers of changes to the silicone compound formulation, raw material suppliers, or curing process? Changes that affect extractables profile require re-qualification.

• Lot-to-lot consistency: What process controls ensure that extractables profile is consistent between production lots? Request extractables data from multiple lots.

• Post-cure process: Does the supplier conduct post-cure (secondary cure at elevated temperature) to reduce volatile siloxane content? What are the post-cure parameters?

• Washing/extraction process: For ultra-low extractables grades, what washing or extraction process is used? What is the validation basis?

• Cleanroom particle monitoring: For pharmaceutical-grade tubing, continuous particle monitoring with documented records is required — not just periodic spot checks.

For a complete remote audit protocol including specific questions for pharmaceutical supplier qualification, see: How to Conduct a Remote Factory Audit of a Chinese Medical Silicone Manufacturer

For guidance on supply chain risk management for critical pharmaceutical silicone components, see: Medical Silicone Supply Chain Risk Management: How to Build a Resilient Sourcing Strategy

Part 10: Silicone vs. Alternative Tubing Materials for Pharmaceutical Applications

Pharmaceutical engineers sometimes consider alternative tubing materials — C-Flex, Tygon, Pharmed BPT, or fluoropolymer tubing — for specific applications. Understanding the trade-offs is essential for material selection decisions.

Selection guidance:

• Standard bioprocessing, CIP/SIP, peristaltic pump: Platinum-cured silicone — best overall balance

• Organic solvent contact (>50% organic): PTFE/FEP — silicone swells in concentrated organics

• Ultra-low extractables, no steam required: C-Flex or Pharmed BPT — lower extractables than silicone in some organic media

• Highest chemical resistance, no flexibility required: PTFE — but not suitable for peristaltic pump use

Chensheng Medical Pharmaceutical-Grade Silicone Tubing

Jinan Chensheng Medical Technology Co., Ltd. supplies pharmaceutical-grade platinum-cured silicone tubing to bioprocessing facilities, pharmaceutical manufacturers, and single-use system integrators globally.

Our pharmaceutical-grade product range:

Documentation provided for all pharmaceutical-grade products:

• Material composition statement with CAS numbers

• USP <665> extractables study report

• ICP-MS elemental impurities data (ICH Q3D)

• Lot-specific Certificate of Analysis

• ISO 13485 certificate

• Change notification commitment (Quality Agreement)

→ Request Pharmaceutical-Grade Silicone Tubing Samples→ Request Our Full E&L Documentation Package→ Discuss Your Bioprocessing Application Requirements

Frequently Asked Questions (FAQ)

Q1: What is the difference between extractables and leachables, and which one do I need to test for my pharmaceutical application?

A: Extractables are compounds released under exaggerated laboratory conditions — they represent the worst-case chemical profile of the material. Leachables are compounds that actually migrate into your drug product under real process conditions. You need both: extractables testing first to characterize the material and identify what could potentially leach, then leachables testing to confirm what actually does leach under your specific process conditions and at what concentrations. The extractables study is conducted by the tubing supplier (or by you using supplier-provided samples). The leachables study is conducted by you using your actual drug product or a representative surrogate under your actual process conditions.

Q2: Does USP Class VI compliance mean silicone tubing is qualified for pharmaceutical manufacturing?

A: No. USP Class VI is a biological safety test that evaluates acute animal reactions — it does not characterize extractables, does not meet USP <665> requirements, and does not satisfy ICH Q3D elemental impurity requirements. USP Class VI is a necessary baseline for any patient-contact material, but it is not sufficient for pharmaceutical manufacturing qualification. For pharmaceutical applications, you need USP <665> extractables data, ICH Q3D elemental impurities data (particularly platinum for platinum-cured silicone), and a toxicological risk assessment for identified extractables above the AET.

Q3: How do I determine the Analytical Evaluation Threshold (AET) for my pharmaceutical application?

A: The AET is calculated based on the maximum daily dose of your drug product and the Threshold of Toxicological Concern (TTC). For non-genotoxic compounds, the TTC is 1.5 μg/day per ICH M7. The AET calculation: AET=1.5 μg/dayMaximum Daily Dose (mL/day)×Extraction RatioAET=Maximum Daily Dose (mL/day)×Extraction Ratio1.5μg/day. For a drug product with a maximum daily dose of 1,000 mL/day and an extraction ratio of 1 (worst case), the AET would be 1.5 ppb. Any extractable identified above this concentration requires a compound-specific toxicological assessment. Your regulatory affairs team or a toxicologist should confirm the AET calculation for your specific product and route of administration.

Q4: We are building a new bioreactor suite using single-use systems. What silicone tubing documentation do we need from our supplier before starting GMP manufacturing?

A: Before starting GMP manufacturing with single-use silicone tubing, you need: (1) USP <665> extractables study report for the specific tubing grade and size; (2) ICP-MS elemental impurities data including platinum; (3) Gamma sterilization validation report (if using pre-sterilized tubing); (4) Post-irradiation extractables data (measured after 2–4 week hold); (5) Cell culture compatibility data if the tubing contacts cell culture media; (6) Lot-specific Certificate of Analysis for each production lot; (7) Signed Quality Agreement with change notification provisions; (8) ISO 13485 certificate (current, scope-verified). This documentation package supports your equipment qualification (IQ/OQ/PQ) and your drug product regulatory submission.

Q5: How many CIP and SIP cycles can platinum-cured silicone tubing withstand before replacement?

A: Well-manufactured platinum-cured silicone tubing can withstand 100–200 autoclave cycles (121°C) with minimal property change (< 5 Shore A units, < 5% tensile strength reduction). For CIP cycles with standard caustic (1–2% NaOH at 70°C), 100+ cycles are achievable without significant degradation. However, the replacement interval should be determined by your specific CIP/SIP conditions and validated by periodic property testing — not assumed from generic data. Establish a tubing replacement schedule based on: (1) cycle count; (2) periodic visual inspection for surface changes, cracking, or tackiness; (3) periodic dimensional measurement to detect compression set accumulation in pump segments; (4) periodic extractables testing to detect any increase in extractables after extended cycling.

Q6: Can I use the same silicone tubing specification for both my bioreactor connections and my fill-finish fluid path?

A: Not typically. Bioreactor connections and fill-finish fluid paths have different risk profiles and therefore different extractables requirements. Fill-finish fluid paths contact the final drug product at its full concentration immediately before filling into patient-administered containers — this is the highest-risk contact in the entire manufacturing process. Ultra-low extractables silicone (post-cured, TOC < 1 ppm) is required for fill-finish applications. Bioreactor connections contact cell culture media (not the final drug product) and can use standard pharmaceutical-grade silicone (TOC < 5 ppm). Using the same specification for both is technically possible if you qualify to the higher fill-finish standard, but it adds unnecessary cost to lower-risk applications.

Q7: Our drug product contains 30% ethanol. Is platinum-cured silicone compatible?

A: Platinum-cured silicone has moderate compatibility with ethanol/water mixtures. At 30% ethanol, silicone experiences minor swelling (typically 2–5% volume increase) and a corresponding slight increase in extractables compared to aqueous-only contact. For most applications, 30% ethanol contact is acceptable with platinum-cured silicone, but you should: (1) verify dimensional stability by measuring ID and OD before and after 24-hour contact with your 30% ethanol formulation; (2) conduct extractables testing in your actual formulation (not just water) to confirm extractables remain within acceptable limits; (3) assess whether the slight swelling affects pump segment performance if the tubing is used in a peristaltic pump. For ethanol concentrations above 70%, consider fluoropolymer tubing (PTFE/FEP) — silicone swelling becomes significant and may affect dimensional precision and extractables profile.

Related Articles:

• Platinum-Cured vs. Peroxide-Cured Silicone: Which Is Better for Your Application?

• USP Class VI, ISO 10993, and FDA 21 CFR 177.2600: Which Certification Do You Actually Need?

• Sterilization Methods for Medical Silicone Products: Autoclave, EtO, Gamma, and E-Beam Compared

• Silicone Shore A Hardness Explained: How to Select the Right Durometer for Your Medical Application

• Silicone Components for Infusion and IV Therapy Devices: Compliance Requirements and Supplier Selection

• How to Conduct a Remote Factory Audit of a Chinese Medical Silicone Manufacturer

• Medical Silicone Supply Chain Risk Management: How to Build a Resilient Sourcing Strategy

• How to Choose a Reliable Medical Silicone Manufacturer in China